SELP and Schnyder corneal dystrophy: Some of the key ongoing clinical trials assessing the efficacy and safety of Novartis SCD medicines in patients from SSA are a phase 1/2 trial for hydroxyurea (NCT01966731), and a phase 3 clinical trial for the new SCD treatment crizanlizumab (an anti-P-selectin monoclonal antibody; NCT03814746).